Ist der Einsatz von Parathormon bei sekundärer Osteoporose im Rahmen von entzündlich-rheumatischen Erkrankungen sinnvoll?

Zusammenfassung

Entzündlich-rheumatische Erkrankungen gehen oft mit einer sekundären Osteoporose einher. Die Ätiologie des Knochenmasseverlustes ist multifaktoriell, wobei der Entzündungsaktivität eine zentrale Rolle zukommt. Die häufig eingesetzten Glukokortikoide nehmen zudem über verschiedene Mechanismen Einfluss auf den Knochenstoffwechsel und die Knochenmasse. Ob der Einsatz von Parathormon bei sekundärer Osteoporose im Rahmen von entzündlich-rheumatischen Erkrankungen sinnvoll ist, wird in dem vorliegenden Artikel abgehandelt.

Abstract

Inflammatory rheumatic diseases are often accompanied with secondary osteoporosis. The aetiology of bone loss is due to many factors, a central role is played by the inflammatory activity. Glucocorticoids that are often applied in the therapy regime influence bone metabolism and bone mass in different ways. Whether or not the administration of the osteoanabolic parathormone is a reasonable therapeutic option in inflammatory rheumatic diseases with secondary osteoporosis is discussed in the present overview.

Schlüsselwörter

entzündlich-rheumatische Erkrankungen - Osteoporose - Parathormon

Key words

inflammatory rheumatic diseases - secondary osteoporosis - parathyroid hormone

• Literatur

• 1 Lange U, Müller-Ladner U, Pfeilschifter J. Osteoporose. Leitliniengerechte Prophylaxe. Diagnostik und Therapie. Internist 2011; 52: 843-854
• 2 Lehmann G, Wolf G. Teriparatid – ein Überblick. Arzneimitteltherapie 2010; 28: 277-282
• 3 Brown EM. Physiology and pathopyhsiology of the extracellular calcium-sensing-receptor. Am J Med 1999; 106: 238-253
• 4 Kronenberg HM. PTH: mechanism of action, in primer on metabolic bone diseases. In: Favus M. (ed.) American Society of Bone and Mineral Research. 3^rd edition Lippincott Raven; 1996: 68-70
• 5 Morley P, Whitfield JF, Willick GE. Parathyroid hormone: an anaboloic treatment for osteoporosis. Curr Pharm Des 2001; 7: 671-687
• 6 Ma YL, Cain RL, Halladay DL et al. Catabolic effects of continous human PTH (1-38) in vivo is associated with substained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001; 142: 4047-4054
• 7 Fu Q, Jilka RL, Manolagas SC et al. Parathyroid hormone stimulates receptor activator of NF kappa b ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem 2002; 277: 48868-48875
• 8 Lee SK, Lorenzo JA. Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures. Bone 2002; 31: 252-259
• 9 Bauer W, Aub JC, Albright F. Studies of calcium and phosphorus metabolism. V. A study of the bone trabecular as a readily available reserve of calcium. J Exp Med 1929; 49: 145-161
• 10 Niall HD, Sauer RT, Jacobs JW et al. The amino-acid sequence of the amino-terminal 37 residues of human parathyroid hormone. Proc Natl Acad Sci USA 1974; 71: 384-388
• 11 Reeve J, Meunier PJ, Parsons JA et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 1980; 280: 1340-1344
• 12 Dempster DW, Cosman F, Kurland ES et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001; 16: 1846-1853
• 13 Jiang Y, Zhao JJ, Mitlak BH et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18: 1932-1941
• 14 Compston JE. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 2007; 40: 1447-1452
• 15 Lange U, Neumann E. Knochen und Entzündung – molekulare Mechanismen, neue pathophysiologische Stoffwechselwege und innovative Therapieansätze. Osteologie 2009; 1: 41-44
• 16 Lange U. Osteoporose und Rheuma – molekulare Mechanismen. Orthopädische Praxis 2011; 47 (07) 352-356
• 17 Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289: 1504-1508
• 18 Dobnig H, Turner RT. The effects of programmes administration of human parathyroid hormone fragment 1-34 on bone histomorphometry and serum chemistry in rats. Endocrinology 1997; 138: 4607-4612
• 19 Jilka RL, Weinstein RS, Bellido T et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999; 104: 439-446
• 20 Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995; 136: 3632-3638
• 21 Rodan GA, Martin TJ. Role of osteoblasts in hormonal control of bone resorption – a hypothesis. Calcif Tissue Int 1981; 33: 349-351
• 22 Lange U, Teichmann J, Strunk J et al. Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis. Osteoporos Int 2005; 16: 1999-2004
• 23 Oelzner P, Müller A, Deschner F et al. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 1998; 62: 193-198
• 24 Oelzner P, Buttgereit F, Demary W et al. Mechanismen des Knochenmasseverlustes bei rheumatoider Arthritis. Darstellung anhand einer Kasuistik. Z Rheumatol 2007; 66: 337-340
• 25 Schett G, Kiechl S, Weger S et al. High-sensitive C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 2006; 166: 2495-2501
• 26 Hofbauer L, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490-495
• 27 Neumann E, Gay S, Müller-Ladner U. The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. Arthritis Rheum 2005; 52: 2960-2967
• 28 Allali F, Breban M, Porcher R et al. Increase in bone mineral density of patients with spondylarthropathy treated with anti-tumour necrosis factor α. Ann Rheum Dis 2003; 62: 347-349
• 29 Lange U, Teichmann J, Müller-Ladner U et al. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody: a prospective open-label pilot study. Rheumatol. 2005 44. 1546-1548
• 30 Vis M, Havaardsholm EA, Haugeberg G et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and RANKL serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1495-1499
• 31 Neumann E, Schett G. Knochenstoffwechsel. Z Rheumatol 2007; 66: 286-289
• 32 Sato K, Suematsu A, Okamoto K et al. Th 17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 2673-2682
• 33 Lubberts E, Koenders MI, Oppers-Walgreen B et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2005; 50: 650-659
• 34 Liu XH, Kirschenbaum A, Yao S et al. Interactive effect of interleukin-6 and prostaglandine E2 on osteoclastogenesis via OPG/RANKL/RANK system. Ann N Y Acad Sci 2006; 1068: 225-233
• 35 Wong PK, Quinn JM, Sims NA et al. Interleukin-6 modulates production of T lyphocytes-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 2006; 54: 158-168
• 36 Lange U. Aktualisierte DVO-Leitlinie Osteoporose 2009 – Glukokortikoide und andere Risikofaktoren. Orthopädie & Rheuma 2010; 5: 37-40
• 37 Saag KG, Shane E, Boonen S et al. Teriparatide or alendronate in Glukokorticoid-induced osteoporosis. N Engl J Med 2007; 357 (20) 2028-2039
• 38 Langdahl BL, Marin F, Shane E et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 2009; 20 (12) 2095-2104
• 39 Dobnig H, Warner MR, Langdahl BL et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis. Effects of gender and postmenopausal status – 24month results. Bone 2009; 44: S212